Epidermal growth factor receptor derived peptide vaccination to prevent lung adenocarcinoma formation: An in vivo study in a murine model of EGFR mutant lung cancer. Mol Carcinog 2016 Nov;55(11):1517-1525
Date
09/09/2015Pubmed ID
26346412Pubmed Central ID
PMC6019616DOI
10.1002/mc.22405Scopus ID
2-s2.0-84941114100 (requires institutional sign-in at Scopus site) 26 CitationsAbstract
The ability to prevent disease is the holy grail of medicine. For decades, efforts have been made to extend the successes seen with vaccination against infectious diseases to cancer. In some instances, preventive vaccination against viruses (prototypically HPV) has successfully prevented tumorigenesis and will make a major impact on public health in the decades to come. However, the majority of cancers that arise are a result of genetic mutation within the host, or non-viral environmental exposures. We present compelling evidence that vaccination against an overexpressed self-tumor oncoprotein has the potential to prevent tumor development. Vaccination against the Epidermal Growth Factor Receptor (EGFR) using a multipeptide vaccine in a preventive setting decreased EGFR-driven lung carcinogenesis by 76.4% in a mouse model of EGFR-driven lung cancer. We also demonstrate that anti-EGFR vaccination primes the development of a robust immune response in vivo. This study provides proof of concept for the first time that targeting tumor drivers in a preventive setting in lung cancer using peptide vaccination can inhibit tumorigenesis and may provide useful clinical insights into the development of strategies to vaccinate against EGFR in populations where EGFR-mutant disease is highly prevalent. © 2015 Wiley Periodicals, Inc.
Author List
Ebben JD, Lubet RA, Gad E, Disis ML, You MMESH terms used to index this publication - Major topics in bold
AnimalsCancer Vaccines
Cell Line, Tumor
ErbB Receptors
Gene Expression Regulation, Neoplastic
Humans
Lung Neoplasms
Mice
Mice, Transgenic
Mutation
Peptides
Vaccination
